ALK and non-small cell lung carcinoma: In a clinical trial involving 572 NSCLC patients with high PD-L1 expression and wild-type EGFR and ALK, the Atezolizumab group had a significantly higher median overall survival than the chemotherapy group (7.1 months; p = 0.01) [106].